Business Wire

SONIO

Share
French Startup Sonio raises €10M through the European Innovation Council Accelerator to improve the health of women and children through AI

Sonio announces a €10M fundraising through the European Innovation Council Accelerator, the leading fund in supporting European deep-tech companies. For this cohort, among 1092 projects submitted, only 78 companies were selected by the EIC Accelerator. This fundraising (€2.5M in grant and €7.5M in equity investment) comes in addition to the €5M previously raised with Elaia, OneRagtime and Bpi France in June 2022. It will support Sonio, a company that empowers fetal medicine professionals and secures pregnancy ultrasounds through AI, to accelerate the release of new features on the platform, such as embedded image recognition and genomics. A great opportunity, also, to gain momentum for the French startup’s market entry in the USA, as well as ramp up sales in Europe and India.

Sonio brings together unique expertise from the fields of fetal medicine, artificial intelligence, software development and ultrasound imaging to address the 50% of congenital malformations that are not detected before birth and improve access and quality of care for pregnant women and children. Created only a couple of years ago, the startup company leverages 5 years of R&D and clinical development at Ecole Polytechnique, the PRAIRIE Institute and Necker Hospital in Paris. It already provides a comprehensive solution to assist all fetal ultrasound practitioners, from beginners to the most seasoned experts and is already being used by over 250 healthcare professionals.

Receiving such a significant funding from one of the most competitive accelerators in the world is a testament to the innovation Sonio brings to fetal medicine” said Cécile Brosset, Chief Executive Officer and co-Founder of Sonio. « Our hard work has been fruitful. I am now more confident than ever that we can help secure pregnancy care worldwide with collective and artificial intelligence.”

“For us this funding means more research, more clinical studies, more innovation, more patents filed in Europe and ultimately an improved quality of care for patients, wherever they are. We are eager to intensify our scientific partnerships with some of the best experts in Fetal Medicine and Artificial Intelligence.” said Rémi Besson, Chief Scientific Officer and co-Founder of Sonio.

Inspired by the company’s mission and in just 2.5 years, Sonio’s multidisciplinary team has already brought 2 products to market:

  • Sonio Diagnostics, designed for expert diagnostic ultrasounds, was CE marked and found its first clients in record time.
  • Sonio Pro, tailored to secure and bring more efficiency to routine pregnancy ultrasounds, was launched in October and has already convinced customers in Europe.

Several partnerships have already been signed, with Samsung France, one of the main women’s health ultrasound manufacturers, but also with specialized distributors (Lifecell in India, Manager Systems in Brazil, Dynamic Medicals in Nigeria).

“This funding from EIC will allow us to accelerate our commercial development in the USA and in Europe, thanks to faster innovation and better market access. We will also be able to initiate more distribution partnerships in countries where access to healthcare is scarce, thus helping us to fulfill our mission, which is to improve access and quality of care of women and children.” said Dagmar Nuber, Chief Business Officer and co-Founder at Sonio.

About Sonio

Founded in 2020, Sonio is the only SaaS platform that empowers healthcare professionals to secure prenatal care by combining technological innovation, medical expertise, and collective intelligence. It provides a unique Artificial Intelligence software that associates the knowledge of prenatal medicine practitioners with all types of medical, imaging, genetic and environmental data to optimize prenatal screening and diagnosis.

Created by a team of entrepreneurs, and scientific, medical and tech experts, Sonio is already used by over 250 healthcare professionals.

Sonio is committed to become an “Entreprise à Mission” – a company whose objectives in the social, societal, and environmental fields are aligned with this purpose and set out in its by-laws, as defined by the 2019 PACTE law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005108/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye